The Accountability in Foreign Animal Research Act forbids the Secretary of Health and Human Services from directly or indirectly conducting biomedical research that involves testing on vertebrate animals in facilities located in, or owned or controlled by, four enumerated foreign countries (China including Hong Kong; Iran; North Korea; Russia) and any other country the Secretary later designates after consultation with State and Defense. The prohibition also reaches funding relationships — grants, subgrants, contracts, cooperative agreements, and other funding vehicles — that would support such animal research performed by entities based in those countries.
This matters to federal research funders, institutions that receive HHS grants, and investigators who collaborate overseas because it removes a pathway for taxpayer dollars to support in‑vivo work in targeted jurisdictions and imposes a vetting and reporting obligation on HHS when adding countries to the list. The measure is narrow in scope (vertebrate animals; HHS funding) but broad in mechanism (direct or indirect conduct; owned-or-controlled facilities), so it will reshape grant compliance, subaward relationships, and how U.S. teams structure international work involving animal models.
At a Glance
What It Does
The bill bars HHS from conducting or supporting biomedical experiments that involve testing on vertebrate animals in facilities located in, or owned/controlled by, the People’s Republic of China (including Hong Kong), Iran, North Korea, and Russia, and any additional countries the Secretary designates after consulting State and Defense. It reaches both direct HHS activity and support via grants, subgrants, contracts, cooperative agreements, and other funding vehicles.
Who It Affects
HHS and agencies under its umbrella (including grant programs such as NIH), U.S. universities and research institutions that receive HHS funds, investigators who subcontract or collaborate with foreign entities, and foreign entities and facilities based in the named countries that previously had ties to U.S. funding.
Why It Matters
The bill creates an extraterritorial funding restriction focused on animal research that could force institutions to reroute or terminate projects, expand due diligence on foreign collaborations, and set a precedent for targeting specific countries for research funding exclusions on national‑security grounds.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a categorical restriction tied to HHS funding: taxpayer dollars may not be used to support any biomedical research or experimentation that involves testing on vertebrate animals if that work occurs in — or is carried out by — facilities or entities that are located in, owned by, or controlled by certain foreign countries. The text reaches activity HHS 'directly or indirectly' conducts and expressly covers support mechanisms common to federal funding, such as grants, subgrants, contracts, and cooperative agreements.
Four countries are named in the statute: the People’s Republic of China (including Hong Kong), Iran, North Korea, and Russia. Beyond that list, the Secretary of HHS can add other countries to the restriction, but only after consulting with the Secretary of State and the Secretary of Defense.
When the Secretary makes such an addition, the bill requires a written report to specified congressional committees explaining the rationale within 60 days.Practically, the ban applies whenever a U.S. federal award would fund testing on vertebrate animals that is conducted by an entity 'based in' an enumerated country or in a facility located in or owned/controlled by such a country. Because the statute uses expansive language — "directly or indirectly" and "owned or controlled, directly or indirectly" — routine grant management tools (subaward review, foreign component determinations, and flow‑down clauses) will become the operational points for enforcing the prohibition.
The bill does not create new criminal or civil penalties in the text; compliance will be administered through HHS grant terms and processes.The law is narrowly focused on HHS-sourced taxpayer dollars and vertebrate animal testing; it does not by its terms reach non-HHS federal funding, privately funded collaborations, or research that does not involve vertebrate animals. That narrowness reduces its footprint in some respects but also means institutions must track funding sources precisely when planning international work involving animal models.
The Five Things You Need to Know
The statute enumerates four named countries: the People’s Republic of China (including Hong Kong), Iran, the Democratic People’s Republic of Korea, and Russia.
The prohibition applies to testing on vertebrate animals and covers both HHS’s direct conduct of such research and support through grants, subgrants, contracts, cooperative agreements, or other funding vehicles.
HHS may add other countries to the restricted list but must consult with the Secretaries of State and Defense before doing so and submit a detailed report to six specified congressional committees within 60 days explaining the decision.
The bill’s key phrases—'directly or indirectly' and 'owned or controlled, directly or indirectly'—extend the ban to layered arrangements (subawards, intermediaries, and facilities under complex ownership structures), creating broad compliance exposure.
The text sets no new statutory civil or criminal penalties; enforcement would rely on HHS’s administrative grant‑management authorities and conditions of award.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s name: the 'Accountability in Foreign Animal Research Act.' This is purely nominal but signals the policy focus: accountability for taxpayer-funded animal research tied to certain foreign jurisdictions.
Prohibition on HHS-conducted or -supported vertebrate animal research
Sets out the operative ban. The Secretary of HHS 'may not' directly or indirectly conduct biomedical research involving vertebrate animal testing in facilities located in, or owned/controlled by, designated countries, and may not support such research via federal funding vehicles. The provision explicitly lists mechanisms of support (grants, subgrants, contracts, cooperative agreements, or 'other funding vehicles'), which means standard award instruments and flow‑down clauses will be the tools HHS uses to implement the restriction.
Enumerated foreign countries
Names the initial group of covered countries: China (including Hong Kong), Iran, North Korea, and Russia. Including the Hong Kong SAR as part of China is an explicit choice that matters operationally for institutions with collaborators in Hong Kong. The listing is statute‑based rather than rule‑based, which locks those jurisdictions into the prohibition until Congress or the Secretary changes the list through the process in subsection (c).
Process and reporting for adding countries
Authorizes the Secretary to designate additional countries after consulting with the Secretaries of State and Defense and requires a detailed report to six congressional committees within 60 days each time that occurs. The requirement for a written accounting creates an administrative record that could matter in oversight or litigation; it also builds interagency review into the decision to expand the list, tying the research ban to national‑security determinations made with input from State and Defense.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Department of Defense and Department of State — gain an explicit statutory tool to limit taxpayer dollars flowing into animal research infrastructures in adversary nations and to document national‑security rationales when countries are added to the list.
- Congressional oversight committees listed in the bill — receive mandatory reports and rationale when the restricted-country list changes, strengthening legislative visibility into HHS decisions.
- Animal welfare organizations — benefit from a narrower channel for taxpayer-funded animal testing abroad, which aligns with advocacy against public funding for overseas in‑vivo experiments in jurisdictions of concern.
Who Bears the Cost
- HHS and NIH grant management offices — must implement vetting, revise award terms, monitor compliance, and prepare statutory reports without the bill providing implementation funding, increasing administrative workload.
- U.S. universities and research institutions with foreign collaborations — must redesign projects, eliminate or reallocate HHS-funded in‑vivo work tied to listed countries, and perform enhanced due diligence on foreign subrecipients and facility ownership structures.
- Principal investigators and research programs that relied on outsourcing animal studies to facilities in affected countries — will lose a funding pathway and may face delays or higher costs to relocate animal work to domestic or non‑listed foreign sites.
- Foreign entities and facilities based in the listed countries — lose access to U.S. taxpayer-funded support for vertebrate animal research, potentially severing existing partnerships.
Key Issues
The Core Tension
The central dilemma is whether and how to protect national‑security and ethical interests by blocking taxpayer support for animal experiments tied to adversary nations without undermining legitimate scientific collaboration and imposing disproportionate compliance costs on the U.S. research ecosystem; the bill decisively favors restriction and oversight at the cost of operational complexity and potential disruption to research that crosses borders.
The bill uses broad, administrable phrases ('directly or indirectly'; 'owned or controlled, directly or indirectly') without defining key operational terms. That creates immediate compliance questions: how will HHS determine whether a facility is 'owned or controlled' by an entity in a listed country when ownership chains cross jurisdictions, involve shell companies, or include minority investors?
The administrative burden of tracing ownership and control could be significant, and HHS will need to translate statutory language into grant‑management guidance, which itself may be subject to legal challenge.
Another unresolved implementation issue is the boundary between HHS funding and other sources. The statute targets taxpayer dollars administered by HHS, so privately funded collaborations or non‑HHS federal funding aren't directly covered — but projects often mix funding streams.
Institutions will need clear rules about fund segregation and allowable activities. The absence of new penalties means enforcement will rely on award conditions and potential grant remedies (suspension, termination, or clawback), leaving ambiguity about consistency of enforcement and judicial reviewability.
Finally, by limiting only vertebrate animal testing, the bill leaves other collaboration channels (cell culture, computational work, non‑vertebrate models) open, which may incentivize shifting certain activities abroad or to other scientific approaches, with consequences for research pipelines and costs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.